Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 3 boards, counting each seat separately. Longest: Bolt Biotherapeutics Inc., 3 years.
Chief executive roles
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 56
- Earnings growth 15%
- 0
3.7% a year in revenue
-57.6% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Bausch Health Companies Inc. May 19, 202692.2%
-
Pacira BioSciences Inc. June 10, 202587.9%
-
Bausch Health Companies Inc. May 14, 202596.8%
-
Bausch Health Companies Inc. May 15, 202490.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 17, 2026 | Pacira BioSciences Inc. | Sold back to the company | −660,831 | $36.50 | $24,120,326 |
| May 22, 2026 | Bausch Health Companies Inc. | Grant or award | +45,871 | — | — |
| May 19, 2026 | Bausch Health Companies Inc. | Open-market sale | −24,456 | $5.43 | $132,796 |
| Feb 11, 2026 | Pacira BioSciences Inc. | Grant or award | +261,818 | — | — |
| Jan 30, 2026 | Pacira BioSciences Inc. | Shares withheld for tax | −41,488 | $20.54 | $852,164 |
| Jan 2, 2026 | Pacira BioSciences Inc. | Shares withheld for tax | −9,272 | $24.46 | $226,793 |
| Aug 21, 2025 | Bausch Health Companies Inc. | Open-market sale | −15,912 | $7.66 | $121,886 |
| May 16, 2025 | Bausch Health Companies Inc. | Grant or award | +54,347 | — | — |
| Feb 1, 2025 | Pacira BioSciences Inc. | Grant or award | +350,000 | — | — |
| Jan 2, 2025 | Pacira BioSciences Inc. | Shares withheld for tax | −9,375 | $18.33 | $171,844 |
| Aug 12, 2024 | Pacira BioSciences Inc. | Open-market purchase | +8,264 | $12.10 | $99,994 |
| May 17, 2024 | Bausch Health Companies Inc. | Grant or award | +35,360 | — | — |
| Jan 2, 2024 | Pacira BioSciences Inc. | Grant or award | +99,520 | — | — |
Questions about Frank D. Lee
What boards is Frank D. Lee on?
Frank D. Lee sits on the boards of Bausch Health Companies Inc., Bolt Biotherapeutics Inc. and Pacira BioSciences Inc.
What company is Frank D. Lee the CEO of?
Frank D. Lee has been Chief Executive Officer of Pacira BioSciences Inc. since January 2024.
How long has Frank D. Lee served on boards?
Our records show at least 9 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.